Gut Bacteria May Play Role in Crohn's Disease
Study found more harmful strains, fewer helpful ones in people with the inflammatory bowel condition
WebMD News Archive
By Brenda Goodman
WEDNESDAY, March 12, 2014 (HealthDay News) -- The community of bacteria that typically live in the human gut is radically altered in patients with Crohn's disease, a new study shows.
Overall, patients with Crohn's have less diversity among their intestinal bacteria than healthy individuals. And certain types of harmful bacteria appear to be increased in Crohn's patients, while the amounts of beneficial bacteria are decreased, the study found.
Whether those changes are a cause or a consequence of the disease isn't known. But the discovery may help doctors diagnose patients more quickly and it may point the way to new treatments for the disease, which is estimated to affect about 700,000 people in the United States.
For the study, researchers recruited nearly 500 patients who were newly diagnosed with Crohn's disease and more than 200 who were having intestinal problems without inflammation.
Crohn's causes frequent bouts of diarrhea, abdominal pain, cramping and bleeding. The disease may be diagnosed at any age, but it tends to strike early in life. Patients who participated in this study were between the ages of 3 and 17.
Researchers needed to catch the patients early because they wanted to see what was going on in the gut before they had taken any medications that might have changed the bacterial picture.
Doctors took tissue samples from two different places in the gut -- at the beginning and the end of the large intestine. They also collected stool samples from some patients. They then extracted all the genetic material they found. With the help of powerful computers, they targeted almost 46 million specific sequences of DNA present in the samples, says the study published March 12 in the journal Cell Host & Microbe.
These sequences acted like barcodes to identify the genetic signatures of the bacteria that were present, explained study researcher Dirk Gevers, a computational biologist at the Broad Institute, a joint project of MIT and Harvard in Cambridge, Mass.
Researchers confirmed those findings by checking them against samples taken from 800 more people who had participated in other studies.